Recipe for Heart Health: Plant-Based Diet + EVOO Crossover RCT

This 2024 randomized crossover trial, published in the Journal of the American Heart Association, tested whether the amount of extra virgin olive oil consumed within a whole-food plant-based vegan diet meaningfully affected cardiometabolic risk markers in adults at elevated cardiovascular risk. According to PubMed (DOI), both high-EVOO (4 tablespoons/day) and low-EVOO (less than 1 teaspoon/day) phases improved LDL cholesterol, total cholesterol, apolipoprotein B, glucose, and high-sensitivity C-reactive protein -- with the low-EVOO phase showing a slightly larger LDL reduction.

Why This Study Matters

Two of the most evidence-supported dietary patterns for cardiovascular prevention sit in apparent tension. Mediterranean diets, rich in extra virgin olive oil, have strong randomized evidence (PREDIMED) for reducing major cardiovascular events. Whole-food plant-based vegan diets, typically low in added oils, have strong evidence for lowering LDL cholesterol and reversing coronary disease in interventional studies. The two patterns differ substantially in fat intake -- 35 to 45% of calories from fat in a Mediterranean pattern versus often less than 15% in a low-oil vegan pattern.

This trial set up a direct head-to-head comparison within a single patient population. Forty adults with at least 5% 10-year cardiovascular disease risk completed both a four-week high-EVOO plant-based phase (4 tablespoons of EVOO daily, supplying about 48% of calories from fat) and a four-week low-EVOO plant-based phase (less than 1 teaspoon daily, supplying about 32% of calories from fat), separated by a one-week washout.

The design isolates the EVOO variable within an otherwise matched whole-food plant-based diet. Whatever differences emerged would be attributable to the oil intake, not to the underlying dietary pattern.

How It Was Designed

The investigators recruited 40 adults at elevated cardiovascular risk and randomized them to one of two sequences: high-EVOO first then low-EVOO, or low-EVOO first then high-EVOO. Each phase lasted four weeks, with a one-week washout between them. All participants received weekly cooking classes to support adherence to the assigned diets, which is a methodological strength: it operationalized the dietary patterns rather than relying on participants to figure them out.

The high-EVOO phase supplied 4 tablespoons of extra virgin olive oil per day (approximately 50 mL), driving fat to 48% of total energy intake. The low-EVOO phase supplied less than 1 teaspoon of EVOO per day, with fat at 32% of total energy intake. The macronutrient profile in both phases was otherwise plant-based and whole-food: legumes, whole grains, vegetables, fruits, nuts, seeds, and some soy products.

The primary outcome was change in LDL cholesterol from baseline. Secondary outcomes included total cholesterol, apolipoprotein B, HDL cholesterol, triglycerides, glucose, and high-sensitivity C-reactive protein. Linear mixed models analyzed changes from baseline between phases, adjusted for age, sex, and body weight change. The trial was registered at ClinicalTrials.gov (NCT04828447).

What They Found

Both diet phases produced significant improvements across multiple cardiometabolic markers compared to participants' baseline diets:

Biomarker	High-EVOO	Low-EVOO	What It Measures
LDL cholesterol (Period 1)	-16.7 mg/dL	-25.5 mg/dL	Atherogenic cholesterol
Total cholesterol	Reduced (p<0.05)	Reduced (p<0.05)	Total blood cholesterol
Apolipoprotein B	Reduced (p<0.05)	Reduced (p<0.05)	Atherogenic particle count
HDL cholesterol	Reduced (p<0.05)	Reduced (p<0.05)	Protective cholesterol
Glucose	Reduced (p<0.05)	Reduced (p<0.05)	Fasting blood sugar
hs-CRP	Reduced (p<0.05)	Reduced (p<0.05)	Systemic inflammation

Green indicates a favorable direction vs. baseline diet. Both EVOO levels improved cardiometabolic markers; the low-EVOO phase showed slightly larger LDL reductions when it came first in the sequence.

The diet-sequence interaction is the most interesting finding. When participants went from baseline to low-EVOO first, LDL dropped by 25.5 mg/dL. When they then transitioned from low-EVOO to high-EVOO, LDL rose by 15.8 mg/dL. The reverse sequence -- high-EVOO first, then low-EVOO -- showed an LDL drop of 12.7 mg/dL on the transition to low-EVOO.

Reading the Results

The findings group into two distinct observations worth understanding.

Both plant-based diets improved cardiometabolic markers substantially. Compared to participants' baseline (typical American) diets, both the high-EVOO and low-EVOO plant-based diets reduced LDL cholesterol, total cholesterol, apolipoprotein B, glucose, and hs-CRP. The whole-food plant-based foundation -- legumes, whole grains, vegetables, fruits, nuts, seeds -- carried the dominant cardiometabolic benefit, regardless of EVOO quantity. This is consistent with the broader plant-based diet literature, including the work of Esselstyn and Ornish in interventional reversal trials.

Adding 4 tablespoons of EVOO on top of an already low-LDL plant-based diet did not further lower LDL. The sequence analysis revealed that when EVOO intake increased from low to high within an already established plant-based pattern, LDL rose by about 16 mg/dL. The interpretation is not that EVOO is bad for LDL -- mechanistic and PREDIMED-era data show otherwise. The interpretation is more nuanced: in a population that has already adopted a whole-food plant-based diet and achieved substantial LDL reduction, further increases in fat intake (even from EVOO) may not produce additional LDL benefit and may modestly attenuate it. The benefit of EVOO in PREDIMED was demonstrated against a Mediterranean-style baseline diet, not against a low-fat plant-based baseline.

What Didn't Change

The trial was small (40 participants) and short-duration (4 weeks per phase). It can detect biomarker shifts but cannot establish whether the LDL differences would translate to actual cardiovascular event differences over years of follow-up. PREDIMED, with 7,447 participants and 4.8 years of follow-up, remains the definitive evidence on EVOO-supplemented Mediterranean diets and cardiovascular events.

The trial also does not address EVOO consumption in the absence of a plant-based pattern. Most U.S. adults eating standard Western diets would likely see LDL benefit from adding EVOO, especially if it displaces saturated fats. The finding here is specific to the comparison within an already established whole-food plant-based pattern.

Broader Context

This trial contributes to a refined understanding of how dietary fat quantity and quality interact with the underlying dietary pattern. PREDIMED (2013, republished 2018 in NEJM) demonstrated 30% lower major cardiovascular events with a Mediterranean diet supplemented with EVOO compared to a low-fat control diet. The Guasch-Ferre 2022 Harvard cohort showed 19% lower all-cause mortality with higher olive oil intake in 92,383 U.S. adults. The 2019 Schwingshackl network meta-analysis showed high-phenolic EVOO outperformed refined olive oil for LDL, oxidized LDL, and systolic blood pressure.

The 2024 Krenek trial adds a contextual modifier: against a baseline of typical Western eating, EVOO is reliably beneficial. Against a baseline of low-fat whole-food plant-based eating, additional EVOO may not produce further LDL reduction. The takeaway is not a contradiction but a recognition that diet effects compound and that the same nutrient can produce different marginal effects depending on the diet it's added to.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg of hydroxytyrosol and derivatives per day. The polyphenol-specific benefit on oxidized LDL was not the primary outcome of this trial.

Related Research

Continue exploring olive oil and polyphenol science:

• PREDIMED Republished: Mediterranean Diet + EVOO Cut Major CV Events by 30%
• CORDIOPREV: 7 Years of Mediterranean Diet for Secondary CV Prevention
• American Heart Association 2021 Dietary Guidance: Olive Oil's Role

Source: View the original study on PubMed

Olivea's Dosage

This trial used 4 tablespoons (about 60 grams) of EVOO daily in the high-intake phase and less than 1 teaspoon (less than 5 grams) in the low-intake phase. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams; daily intake in the range of 1 to 2 tablespoons is consistent with the cohort evidence on cardiovascular protection and below the threshold where additional fat intake may attenuate LDL reductions in plant-based dieters. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.